Results 71 to 80 of about 136,322 (339)

SARS‐CoV‐2 Is Linked to Brain Volume Loss in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The impact of SARS‐CoV‐2 infection on brain and spinal cord pathology in patients with multiple sclerosis (pwMS) remains unclear. We aimed to describe changes in brain lesion activity and brain and spinal cord volumes following SARS‐CoV‐2 infection.
Tomas Uher, Dominika Stastna, Ingrid Menkyova, Vaclav Capek, Jiri Lindner, Petra Nytrova, Jan Krasensky, Eliza Varju, Miguel D'haeseleer, Eva Kubala Havrdova, Dana Horakova, Manuela Vaneckova, Niels Bergsland   +12 more
wiley   +1 more source

CD20 antibody primes B lymphocytes for type I interferon production. [PDF]

PLoS ONE, 2013
CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases.
Dongsheng Xu, Andrew Staedman, Luwen Zhang   +2 more
doaj   +1 more source

Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan, María A. Piedrabuena, María A. Zarate, Sofía Rodríguez Murúa, Ezequiel I. Surace, Mauricio F. Farez, Marcela P. Fiol, María C. Ysrraelit, Jorge Correale   +8 more
wiley   +1 more source

TGF-β-responsive CAR-T cells promote anti-tumor immune function. [PDF]

, 2018
A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant.
Chang, ZeNan L, Chen, Yvonne Y, Hou, Andrew J, Lorenzini, Michael H, Zah, Eugenia   +4 more
core   +1 more source

Relevance of Kappa and Lambda Free Light Chains in Autoimmune Astrocytopathy Associated With Anti‐GFAP Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction The kappa‐free light chain (κ‐FLC) index is known to be highly sensitive and specific for diagnosing multiple sclerosis (MS), while little is understood about lambda (λ)‐FLC. This study assessed the κ‐FLC and λ‐FLC indices in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
Michael Levraut, Romain Marignier, Mikael Cohen, Jeanne Benoit, Cassandre Landes‐Chateau, Elisabeth Maillart, Marion Cremoni, Barbara Seitz‐Polski, Anne‐Laurie Pinto, Pauline Dumez, Jérôme Honnorat, Christine Lebrun‐Frenay   +11 more
wiley   +1 more source

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis

Haematologica, 2010
Background Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin’s lymphoma has significantly improved outcome. Despite this success, about half of the patients do not respond to treatment
Tom van Meerten, Henk Rozemuller, Samantha Hol, Petra Moerer, Mieke Zwart, Anton Hagenbeek, Wendy J.M. Mackus, Paul W.H.I. Parren, Jan G.J. van de Winkel, Saskia B. Ebeling, Anton C. Martens   +10 more
doaj   +1 more source

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies

Oncotarget, 2016
Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies.
Jahn, L., Steen, D.M. van der, Hagedoorn, R.S., Hombrink, P., Kester, M.G.D., Schoonakker, M.P., Ridder, D. de, Veelen, P.A. van, Falkenburg, J.H.F., Heemskerk, M.H.M.   +9 more
openaire   +5 more sources

Response to: Monoclonal antibodies targeting CD20 [PDF]

mAbs, 2013
Dear Editor, Please allow us to briefly reply to the comments by Dr. Goldenberg and colleagues. As stated in the disclosures, some authors are employees of Roche Glycart AG or Roche Diagnostics GmbH and have contributed to the (non-) clinical development of the glycoengineered Type II CD20 antibody GA101 (obinutuzumab).
Wolfgang Schäfer, Pablo Umana, Christian Klein, Gerhard Niederfellner, Alfred Lammens, Manfred Schwaiger, Karl-Peter Hopfner, Guy Georges, Ekkehard Mössner   +8 more
openaire   +3 more sources

Paroxysmal Dyskinesias Secondary to HHV‐6A Encephalitis: The First Case Report and Literature Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paroxysmal dyskinesias encompasses a spectrum of conditions marked by intermittent involuntary movements, with paroxysmal kinesigenic dyskinesias being the most common phenotype. Central nervous system infection is a rare cause of paroxysmal dyskinesias.
Zhuoran Wang, Haiting Li, Xiaoping Du, Qiong Wang, Yating Zhang, Huifang Wang   +5 more
wiley   +1 more source

Supporting children with genetic syndromes in the classroom: the example of 22q deletion syndrome [PDF]

, 2013
An increasing number of children are likely to have a known genetic cause for their special educational needs. One such genetic condition is 22q11.2 deletion syndrome (22qDS), a genetic syndrome associated with early speech and language difficulties ...
Reilly, C, Stedman, L
core   +1 more source